Leo Cancer Care Secures $65 Million Series D Funding to Expand Upright Cancer Imaging and Treatment Platform
Leo Cancer Care has announced the successful completion of an oversubscribed $65 million Series D financing round, providing the company with significant new resources to accelerate the commercialization of its innovative upright cancer imaging and radiotherapy platform. The investment marks another major milestone for the medical technology company, which is working to transform how cancer patients are diagnosed and treated by designing imaging and radiation therapy systems around the body’s natural upright position rather than the traditional lying-down approach.
The financing round was led by Silicon Valley investment firm Yu Galaxy and attracted participation from new investor Eventide Asset Management, while also receiving continued backing from the company’s existing investors. The strong interest from both new and returning investors reflects growing confidence in Leo Cancer Care’s technology platform, commercial strategy, and vision for improving access to advanced cancer treatment worldwide.
The newly raised capital will be used to expand manufacturing capacity, accelerate commercial deployment of the company’s upright technologies, and support continued product development and clinical research across its comprehensive imaging and treatment platform. Leo Cancer Care is also preparing to broaden its global footprint as more healthcare providers adopt upright imaging and radiotherapy systems.
Accelerating the Next Generation of Cancer Care
Leo Cancer Care has built its platform around a simple yet transformative concept: because people naturally spend most of their lives in an upright position, cancer imaging and radiation treatment should be performed in that same orientation whenever possible.
Traditional radiation therapy and diagnostic imaging are typically conducted while patients lie flat on their backs. While this approach has been standard practice for decades, emerging research suggests that imaging and treatment performed with patients sitting upright may improve anatomical consistency and organ stability for certain clinical applications. Better reproducibility of patient positioning has the potential to improve treatment precision while also enhancing patient comfort.
Rather than simply redesigning one component of radiation therapy, Leo Cancer Care has developed an integrated ecosystem that spans the entire patient journey—from diagnostic imaging and treatment planning to both proton and photon radiation therapy. Every element of the platform utilizes the same upright architecture, creating a unified workflow that supports consistent patient positioning throughout care.
The company believes this integrated strategy can help improve efficiency while simplifying treatment delivery for healthcare providers.
Funding to Expand Manufacturing and Commercial Deployment
The proceeds from the Series D financing will enable Leo Cancer Care to significantly expand production of its technologies while supporting commercial installations across new healthcare facilities.
In addition to increasing manufacturing capacity, the company plans to invest in:
- Commercial deployment of upright imaging systems
- Expansion of proton therapy installations
- Development of photon therapy solutions
- Continued clinical research and validation studies
- Product innovation across the integrated platform
- Global commercialization efforts
These investments are intended to accelerate adoption of upright imaging and treatment technologies while supporting broader access to advanced radiation therapy.
Growing Clinical Adoption
Momentum behind Leo Cancer Care’s technology has continued to grow as leading cancer centers begin integrating upright treatment into clinical practice.
Among the most significant milestones occurred on June 4, 2026, when Stanford Medicine performed the world’s first compact upright proton therapy treatment using Leo Cancer Care’s Marie® platform. The historic procedure involved treating a seven-year-old child with a complex brain tumor, demonstrating the clinical feasibility of the company’s innovative treatment approach.
The successful treatment represented an important step toward validating upright proton therapy in real-world clinical settings.
Beyond Stanford, several other major healthcare organizations are adopting the company’s technology.
Institutions including Dana-Farber Cancer Institute and McLaren Health Care have incorporated Leo Cancer Care’s upright platform into their clinical programs. Adoption across both internationally recognized academic medical centers and regional community health networks demonstrates the broad applicability of the technology across different healthcare environments.
The company believes this growing customer base reflects increasing interest in alternative approaches to radiation oncology that improve accessibility without compromising treatment quality.
A New Approach to Proton Therapy
One of Leo Cancer Care’s most innovative products is its Marie® upright proton therapy platform, which reimagines the physical design of proton therapy systems.
Conventional proton therapy facilities typically rely on enormous rotating gantries weighing several hundred tons to direct proton beams toward tumors from different angles while patients remain stationary.
These massive systems require large treatment rooms, substantial infrastructure investments, and lengthy construction timelines, contributing significantly to the high cost of proton therapy.
Leo Cancer Care takes a fundamentally different approach.
Instead of rotating the heavy treatment equipment around the patient, the Marie® platform keeps the proton beam fixed while gently rotating the seated patient into the desired treatment position.
This engineering innovation dramatically reduces the size and complexity of the treatment system.
According to the company, the resulting treatment room is approximately five times smaller than a conventional gantry-based proton therapy suite based on facility design comparisons.
The smaller footprint enables proton therapy systems to be installed within many existing radiotherapy vaults, eliminating the need for entirely new treatment facilities in some cases.
Reducing infrastructure requirements could make proton therapy financially feasible for many hospitals that previously could not justify the significant capital investment associated with traditional systems.
Expanding Access to Advanced Cancer Treatment
Increasing patient access remains one of Leo Cancer Care’s primary objectives.
Although proton therapy offers important advantages for treating many cancers—particularly pediatric tumors and cancers located near sensitive organs—the technology remains available at relatively few hospitals because of its cost and infrastructure requirements.
By reducing installation costs and simplifying facility design, Leo hopes to expand access to proton therapy in regions where such treatment has historically been unavailable.
The company also believes upright positioning offers additional benefits for certain patient populations.
For example, pediatric patients may benefit from shorter and more efficient treatment workflows, while patients with larger body sizes may experience improved comfort compared with conventional treatment systems.
The company sees these improvements as part of a broader effort to make advanced cancer care available to a more diverse patient population.
FDA-Cleared Upright Imaging Platform
In addition to treatment technologies, Leo Cancer Care has developed an FDA-cleared upright imaging system that serves as the foundation of its integrated platform.
The imaging technology supports radiation treatment planning while also providing opportunities for future expansion into broader radiology applications.
Maintaining the same patient orientation throughout imaging, treatment planning, and therapy may improve workflow consistency while reducing variability between different stages of care.
The company believes this continuity represents an important advantage of its integrated platform compared with traditional systems that often require patients to change positioning between diagnostic imaging and treatment.
Strategic Partnership Signals Industry Momentum
Alongside the financing announcement, Leo Cancer Care also revealed that it has entered into a major strategic partnership with a large international healthcare company.
Although details of the collaboration have not yet been disclosed, the company indicated that additional information will be announced in the coming weeks.
Management described the agreement as an important validation of the growing industry interest in upright cancer imaging and treatment technologies.
The partnership is expected to further strengthen commercialization efforts while supporting continued innovation across the company’s product portfolio.
Leadership Highlights Long-Term Vision
Stephen Towe, Chief Executive Officer and Co-Founder of Leo Cancer Care, said the company has evolved far beyond its original goal of improving radiation therapy.
According to Towe, the organization now aims to fundamentally redesign the entire cancer treatment experience around patients rather than equipment.
He explained that many previous efforts to reduce healthcare costs have focused primarily on simplifying or reducing the capabilities of medical equipment.
Leo Cancer Care has instead pursued a strategy of redesigning treatment delivery to improve efficiency while maintaining advanced clinical capabilities.
The company believes this patient-centered approach can expand access to sophisticated therapies without compromising treatment quality.
Towe added that the new financing provides the resources needed to accelerate development across the company’s complete platform, including imaging, photon therapy, and proton therapy.
Investors Express Confidence
Yu Galaxy Founder PR Yu, whose firm led the financing round, emphasized the significant commercial potential of Leo Cancer Care’s technology.
Yu noted that the company’s upright radiotherapy and radiology innovations have the potential to lower treatment costs while reducing treatment times and expanding access to advanced care.
He highlighted particular benefits for pediatric patients and individuals whose body size can present challenges with conventional treatment systems.
According to Yu, Leo Cancer Care’s technologies could help bring advanced cancer treatment to regions and healthcare systems that have historically lacked access to sophisticated radiotherapy solutions.
He also suggested that installations currently planned across multiple countries illustrate the platform’s growing international appeal, with several deployments representing the first systems of their kind within their respective regions.
With fresh capital, expanding clinical adoption, an FDA-cleared imaging platform, and growing interest from major healthcare providers, Leo Cancer Care is entering an important stage of commercial growth. The company plans to use the Series D investment to scale manufacturing, accelerate installations, and continue advancing its integrated upright cancer care platform across imaging, photon therapy, and proton therapy.
As hospitals increasingly seek innovative ways to improve patient care while managing infrastructure costs, Leo Cancer Care believes its upright approach could reshape how cancer imaging and radiation therapy are delivered. Combined with ongoing clinical validation, strategic industry partnerships, and expanding global adoption, the company is positioning itself to play a significant role in the future evolution of precision oncology, with the goal of making advanced cancer treatment more accessible to patients worldwide.